The Quantgene Story

We envision a future of medicine where all disease is prevented and detected at the earliest stage.

Quantgene unlocks the Deep Human Genome by building and deploying the world’s leading Deep Genomics solution. Our mission is to save lives through early detection, better prevention and more effective cures for all disease, starting with cancer.

Quantgene started in 2015 in a small UC Berkeley Lab under the leadership of Jo Bhakdi and Dr. Monika Hagen. Our theory was that most disease can be detected far earlier than today by introducing quantitative science and a new level of precision into
medical practice. Since then, our team has spent over 4 years building the industry’s best team of pioneers and developing the GRIFFIN Deep Genomics platform. GRIFFIN combines extreme precision sequencing, software and AI technologies to profile cell-free DNA (cfDNA) fragments with unprecedented depth and precision. In 2016, Quantgene launched its first clinical feasibility trial which continues today with the goal of adding 10,000 patient samples to the GRIFFIN platform by 2020.

We are determined to build a future where everyone is protected against most diseases through early detection with our innovative technology.

Get to Know Us

The Quantgene Story

We envision a future of medicine where all the disease is prevented and detected at the earliest stage.

Quantgene unlocks the Deep Human Genome by building and deploying the world’s leading Deep Genomics solution. Our mission is to save lives through early detection, better prevention and more effective cures for all disease, starting with cancer.

Quantgene started in 2015 in a small UC Berkeley Lab under the leadership of Jo Bhakdi and Dr. Monika Hagen. Our theory was that most disease can be detected far earlier than today by introducing quantitative science and a new level of precision into
medical practice. Since then, our team has spent over 4 years building the industry’s best team of pioneers and developing the GRIFFIN Deep Genomics platform. GRIFFIN combines extreme precision sequencing, software and AI technologies to profile cell-free DNA (cfDNA) fragments with unprecedented depth and precision. In 2016, Quantgene launched its first clinical feasibility trial which continues today with the goal of adding 10,000 patient samples to the GRIFFIN platform by 2020.

We are determined to build a future where everyone is protected against most diseases through early detection with our innovative technology.

Get to Know Us